加味消渴康治疗糖尿病肾病临床疗效观察  

Observation of clinical efficacy of modified Xiaokekang for diabetic nephropathy

作　　者：章九红[1] 李文泉[1] 耿建国[2] 杜宇琼[2] 苗力[1] 邢兆宏[1] 张铖[2] 

机构地区：[1]首都医科大学附属北京朝阳医院,北京100020 [2]首都医科大学中医药学院临床基础教研室,北京100069

出　　处：《北京中医药》2015年第1期6-9,共4页Beijing Journal of Traditional Chinese Medicine

基　　金：2011年度首都中医药与护理专项课题(11ZYH01)

摘　　要：目的观察加味消渴康对早期糖尿病肾病(DN)的临床疗效。方法将60例DN患者随机分为2组,治疗组30例,给予加味消渴康治疗;对照组30例,给予血管紧张素Ⅱ受体拮抗剂(ARB)药物治疗,疗程均为3个月。观察2组治疗前后尿白蛋白、血糖、糖化血红蛋白、血β2微球蛋白、尿β2微球蛋白等指标变化,采用中医证候分级计分评价疗效。结果加味消渴康可有效改善DN患者的临床症状,治疗组中医证候疗效明显优于对照组,差异有统计学意义(P<0.05)。治疗组血β2-MG、尿β2-MG水平均较对照组明显降低,差异有统计学意义(P<0.05)。结论加味消渴康对早期DN患者可以发挥调节血糖,减轻肾损害的功效。Objective To observe the clinical efficacy of modified Xiaokekang for diabetic nephropathy （ DN ）. Methods Sixty patients of DN were divided into two groups. 30 patients in the treatment group were treated with modified Xiaokekang, while 30 patients in the control group were treated with angiotensin receptor blocker （ARB）. The treatment was both given for 3 months. Before and after treatment, urinary albumin, blood glucose, glycosylated hemoglobin, blood 132 microglobulin, urinary [32 microglobulin were observed, and TCM syndrome score was used to evaluate the treatment effects. Results The modified Xiaokekang could effectively improve clinical symptoms, and TCM syndrome score in the treatment group was superior to that in the control group （ P 〈 0.05 ）. The blood 132 microglobulin mad urinary 132 microglobulin in the treatment group was lower than that in the control group （P 〈 0. 05 ）. Conclusion The modified Xiaokekang could regulate blood glucose and reduce kidney injury for DN patients at early stage.

关 键 词：加味消渴康 糖尿病肾病 尿白蛋白 疗效 

分 类 号：R259[医药卫生—中西医结合]